

<https://helda.helsinki.fi>

Nagashima-type palmoplantar keratosis in Finland caused by a SERPINB7 founder mutation

Hannula-Jouppi, Katariina

2020-08

Hannula-Jouppi , K , Harjama , L , Einarsdottir , E , Elomaa , O , Kettunen , K , Saarela , J , Soronen , M , Bouchard , L , Lappalainen , K , Heikkilä , H , Kivirikko , S , Seppänen , M R J , Kere , J & Ranki , A 2020 , ' Nagashima-type palmoplantar keratosis in Finland caused by a SERPINB7 founder mutation ' , Journal of the American Academy of Dermatology , vol. 83 , no. 2 , pp. 643-645 . <https://doi.org/10.1016/j.jaad.2019.11.004>

<http://hdl.handle.net/10138/321172>

<https://doi.org/10.1016/j.jaad.2019.11.004>

cc_by_nc_nd

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Journal Pre-proof

Nagashima-type palmoplantar keratosis in Finland caused by a *SERPINB7* founder mutation

Katariina Hannula-Jouppi, MD, PhD, MBA, Liisa Harjama, MD, Elisabet Einarsdottir, PhD, Outi Elomaa, PhD, Kaisa Kettunen, PhD, Janna Saarela, MD, PhD, Minna Soronen, MD, Laura Bouchard, MD, PhD, Katriina Lappalainen, MD, PhD, Hannele Heikkilä, MD, PhD, Sirpa Kivirikko, MD, PhD, Mikko R.J. Seppänen, MD, PhD, Juha Kere, MD, PhD, Annamari Ranki, MD, PhD



PII: S0190-9622(19)33004-X

DOI: <https://doi.org/10.1016/j.jaad.2019.11.004>

Reference: YMJD 13981

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 2 May 2019

Revised Date: 31 October 2019

Accepted Date: 4 November 2019

Please cite this article as: Hannula-Jouppi K, Harjama L, Einarsdottir E, Elomaa O, Kettunen K, Saarela J, Soronen M, Bouchard L, Lappalainen K, Heikkilä H, Kivirikko S, Seppänen MR, Kere J, Ranki A, Nagashima-type palmoplantar keratosis in Finland caused by a *SERPINB7* founder mutation, *Journal of the American Academy of Dermatology* (2019), doi: <https://doi.org/10.1016/j.jaad.2019.11.004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

1 **Article type:** Research Letter

2 **Title:** Nagashima-type palmoplantar keratosis in Finland caused by a *SERPINB7* founder mutation

3 Katariina Hannula-Jouppi, MD, PhD, MBA^{1,2,3}, Liisa Harjama MD¹, Elisabet Einarsdottir, PhD^{2,3,4,5}, Outi

4 Elomaa PhD^{2,3}, Kaisa Kettunen PhD^{6,7}, Janna Saarela MD, PhD^{6,8}, Minna Soronen MD⁹, Laura Bouchard MD,

5 PhD¹, Katriina Lappalainen MD, PhD¹, Hannele Heikkilä MD, PhD¹, Sirpa Kivirikko MD, PhD¹⁰, Mikko RJ

6 Seppänen, MD, PhD¹¹, Juha Kere, MD, PhD^{2,3,4,12}, and Annamari Ranki, MD, PhD¹

7

8 ¹ Department of Dermatology, Skin and Allergy Hospital, University of Helsinki and Helsinki University
9 Hospital, Helsinki, Finland

10 ² Folkhälsan Research Center, Helsinki, and Stem Cells and Metabolism Research Program, Faculty of
11 Medicine, University of Helsinki, Helsinki, Finland

12 ³ Folkhälsan Institute of Genetics, Helsinki, and Research Programs Unit, Molecular Neurology, University of
13 Helsinki, Helsinki, Finland

14 ⁴ Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

15 ⁵ Science for Life Laboratory, Department of Gene Technology, KTH-Royal Institute of Technology, Solna,
16 Sweden

17 ⁶ Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of
18 Helsinki, Helsinki, Finland.

19 ⁷ Laboratory of Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

20 ⁸ Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway

21 ⁹ PEDEGO Research Unit, University of Oulu; Department of Dermatology and Medical Research Center
22 Oulu, Oulu University Hospital, Oulu, Finland

¹⁰ Department of Clinical Genetics and Department of Medical and Clinical Genetics, University of Helsinki
and Helsinki University Hospital, Helsinki, Finland

¹¹ Rare Disease Center, New Children's Hospital, University of Helsinki and Helsinki University Hospital,
Helsinki, Finland

¹² School of Basic and Medical Biosciences, King's College London, London, United Kingdom

28

Corresponding author:

Katariina Hannula-Jouppi, MD, PhD, MBA

Department of Dermatology

PO Box 160 (Meilahdentie 2)

Helsinki University Hospital

00029 HUS, Finland

Email: katariina.hannula-jouppi@hus.fi

36

Funding sources: Helsinki University Hospital Research Funds, Finnish Dermatological Society's (SILY)
grants.

Conflicts of Interest: None declared.

IRB approval status: Reviewed and approved by the Coordinating Ethical Review Board of the Helsinki and
Uusimaa Hospital district, Helsinki, Finland; approval dnro 91/13/03/00/11.

Reprint requests: Not available from the authors.

Manuscript word count: 500 words

44 **Capsule summary word count:** 25

45 **References:** 5

46 **Figures:** 1

47 **Tables:** 1

48 **Supplemental tables:** 2 (available at Mendeley doi: 10.17632/z8tjpfjdj3v.1

49 <http://dx.doi.org/10.17632/z8tjpfjdj3v.1>)

50 **Supplemental texts:** 1 (available at Mendeley doi: 10.17632/z8tjpfjdj3v.1

51 <http://dx.doi.org/10.17632/z8tjpfjdj3v.1>)

52 **Supplemental figures:** 2 (available at Mendeley doi: 10.17632/z8tjpfjdj3v.1

53 <http://dx.doi.org/10.17632/z8tjpfjdj3v.1>)

54 **Keywords:** palmoplantar keratoderma; Nagashima type; SERPINB7; transgradient

55 **Capsule summary**

- 56
- *SERPINB7* mutations in NPPK are not confined to Asian populations.
- 57
- The presence of *SERPINB7* mutations should be tested in patients with NPPK in non-Asian
- 58
- populations.

To the editor: Nagashima-type palmoplantar keratosis (NPPK) is an autosomal recessive PPK caused by mutations in the serpin family B member 7 (*SERPINB7*) gene.¹ It has been reported only in Japanese, Chinese and Korean populations, with a common founder mutation c.796C>T p.(Arg266*).^{1,2,3} NPPK is characterized by well-demarcated, mild, nonprogressive diffuse hyperkeratosis with transgradient erythema expanding onto the dorsal aspect of the hands, wrists and Achilles tendon area. Palmoplantar hyperhidrosis, aquagenic whitening and fungal infections are frequent.^{1,4} Loss of functional *SERPINB7* in skin probably leads to overactivation of intracorneocyte proteases causing skin barrier defects with hyperkeratosis, mild inflammation, and increased water permeability.¹

We report three non-Asian NPPK patients, with a typical NPPK phenotype and homozygous *SERPINB7* mutation. Since the age of two months, the 27-year-old Finnish male proband (P1) had a mild diffuse PPK with a well demarcated erythema extending to the wrist and Achilles tendon area (Fig 1, Table I). His whole exome sequencing (WES) (SuppText1) revealed a homozygous *SERPINB7* c.1136G>A p.(Cys379Tyr) (NM_003784.3) variant (rs201208667) in exon 8 encoding the second-last amino acid of *SERPINB7*. His unaffected mother and sister were heterozygous carriers of the variant. Sanger sequencing among 44 unrelated Finnish PPK patients revealed two other homozygous patients and four heterozygous carriers (Table I). WES of three heterozygous patients (P4-P6) revealed no other likely pathogenic variants or copy-number variations (CNVs) in *SERPINB7* or other genes. WES was unfeasible for P7 but a SNP array for haplotype analysis revealed no other *SERPINB7* variants or CNVs. The cause of their PPK thus remains unknown. Other plausible *SERPINB7* variants were not analyzed in the other patients.

SERPINB7 c.1136G>A p.(Cys379Tyr) has not been reported in NPPK (SuppTable1). It was predicted damaging by SIFT, Polyphen, MutationTaster, LRT and CADD (score 19). Only heterozygous carriers were found in population allele frequency databases (ExAC, GnomAD and SiSu). According to GnomAD, the heterozygous carrier frequency was significantly higher for the Finnish population (0.006397) than for non-Finns (0.00032-0.0014), indicating a 5 to 20-fold enrichment in Finns. A common haplotype spanning 272 kb around the detected variant was shared by P1, P2 and six heterozygous carriers, according to

84 genome wide SNP array data (SuppTable2). The variant thus constitutes a plausible Finnish NPPK founder
85 mutation.

86 P1's skin histology showed non-epidermolytic hyperkeratosis compatible with NPPK. *SERPINB7*
87 immunostaining was strong throughout the stratum spinosum (SS) with most intense staining in stratum
88 granulosum. Heterozygous carriers and healthy controls showed less intense staining throughout the SS
89 and the lower SS was negative (SuppFigure 1). Thus, the c.1136G>A p.(Cys379Tyr) mutation apparently
90 leads to aberrant *SERPINB7* distribution within the SS.

91

92 The c.1136G>A p.(Cys379Tyr) *SERPINB7* variant changes the second-last amino acid cysteine, which is
93 conserved among different species (SuppFigure2). Tertiary structure prediction suggested that the
94 substitution is in the vicinity of the reactive site loop (RSL) where most *SERPINB7* mutations in NPPK are
95 located. The substitution possibly affects the conformational mobility of RSL during the inhibition process.⁵
96 Previously NPPK has been reported exclusively in Asian patients. Our findings encourage assessment for
97 *SERPINB7* mutations in non-Asian individuals with a NPPK-phenotype.

98 **Acknowledgements**

99 All patients and their families are thanked for participation. Alli Tallqvist, Eira Leinonen, Auli Saarinen are
100 thanked for their expertise in the laboratory. The Department of Dermatology, Helsinki University Central
101 Hospital is a healthcare provider of the European Reference Network ERN-SKIN.

102 **Abbreviations**

103 NPPK: Nagashima type palmoplantar keratoderma

104 PPK: palmoplantar keratoderma

105 *SERPINB7*: serpin family B member 7

106 WES: Whole exome sequencing

107 CNV: copy-number variation

108 RSL: reactive site loop

109 SiSU: Sequencing Initiative Suomi project

110 SS: stratum spinosum

111

112 **References:**

- 113 1. Kubo A, Shiohama A, Sasaki T, Nakabayashi K, Kawasaki H, Atsugi T, et al. Mutations in SERPINB7,
114 encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar
115 keratosis. *Am J Hum Genet.* 2013 November 07;93(5):945-56.
- 116 2. Zhang J, Zhang G, Ni C, Cheng R, Liang J, Li M, et al. Nagashima-type palmoplantar keratosis in a Chinese
117 Han population. *Mol Med Rep.* 2016 November 01;14(5):4049-54.
- 118 3. On HR, Lee SE, Nomura T, Miyauchi T, Suzuki S, Shimizu H, et al. Identification of SERPINB7 mutations in
119 Korean patients with Nagashima-type palmoplantar keratosis. *J Dermatol.* 2017 July 01;44(7):840-1.
- 120 4. Yin J, Xu G, Wang H, Zhao J, Duo L, Cao X, et al. New and recurrent SERPINB7 mutations in seven Chinese
121 patients with Nagashima-type palmoplantar keratosis. *J Invest Dermatol.* 2014 August 01;134(8):2269-72.
- 122 5. Gettins PG, Olson ST. Inhibitory serpins. New insights into their folding, polymerization, regulation and
123 clearance. *Biochem J.* 2016 August 01;473(15):2273-93.

124

125

126 **Figure legends**

127 Figure 1. NPPK clinical characteristics. Mild palmoplantar hyperkeratosis with transgredient erythema
128 extending to the wrist and Achilles tendon area in P1 homozygous for *SERPINB7* c.1136G>A.

129

130 **Table legends**

131 Table I. Clinical characteristics of the patients.

132

133 **Supplemental material on Mendeley platform**

134 SuppTable1. *SERPINB7* mutations in NPPK. Founder mutations are highlighted in bold.

135 SuppTable2. Shared haplotype around *SERPINB7* c.1136G>A p.(Cys379Tyr) variant (rs201208667). Two
136 homozygous patients and six heterozygous carriers show the common shared 272 kb haplotype delineated
137 by the black lines. Shared haplotype regions are shaded light grey and the c.1136G>A p.(Cys379Tyr) variant
138 is bolded and shaded dark grey. The haplotypes of P1, P1's mother and sister and P2 extend beyond the
139 region shown.

140 SuppText1. Materials and methods.

141 SuppFigure1. NPPK clinical characteristics and *SERPINB7* immunohistochemistry.

142 SuppFigure2. Conservation of Cys379 among different species and in *SERPIN* family members.

143 **Tables**

144 Table I. Clinical characteristics of the patients.

	P1	P2	P3	P4	P5	P6	P7	P1 mother	P1 sister	NPPK
SERPINB7 c.1136G>A (rs201208667)	A/A	A/A	A/A	G/A	G/A	G/A	G/A	G/A	G/A	-
WES*	+	-	-	+	+	+	-	-	-	
Age years	27	18	11	60	21	12	16	66	32	
Gender	male	male	male	male	female	female	male	female	female	
Age of onset	2 months	birth	1.5 years	Early childhood	Early childhood	birth	9 years	-	-	birth to 9- 10 years
Diffuse mild PPK	+	+	+	+	+	+	+	-	-	+
Transgradient	+	+	+	+	+	+	+	-	-	+
Achilles tendon affected	+	+	+	-	+	+	-	-	-	+
Wrists affected	+	+	+	-	+	+	-	-	-	+
Progredivens	-	-	-	-	-	-	-	-	-	-
Hyperhidrosis	+	+	+	+	+	+	+	-	-	+ /-
Aquagenic whitening	+	+	+	N/A	+	+	-	-	-	+
Fungal infections	+	-	-	-	+	+	+	-	-	+
Knee/elbow hyperkeratosis	-	-	-	-	-	-	-	-	-	+ /-

145 *WES, whole exome sequencing done +/- not done

Journal Pre-proof

